TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28840328

Group type: EXPERIMENTAL
Intervention: 8 mm instruments
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5 mm instruments
Number of subjects: 24
Study: 27633880

Group type: EXPERIMENTAL
Intervention: CRS + HIPEC with lobaplatin 50 mg/m² and docetaxel 60 mg/m² in 6000 mL of normal saline at 43 ± 0.5 °C for 60 min
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CRS + HIPEC with lobaplatin and docetaxel
Number of subjects: 100
Study: 24725787

Group type: EXPERIMENTAL
Intervention: Sitting Active Lag Test
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prone Passive Lag Test
Number of subjects: 56
Study: 22536989

Group type: EXPERIMENTAL
Intervention: PST delivered face-to-face (Group 1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: PST delivered via videophone (Group 2)
Number of subjects: 126
Study: 20118346

Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polidocanol liquid sclerotherapy
Number of subjects: 100
Study: 18209013

Group type: EXPERIMENTAL
Intervention: FLIRI (irinotecan 180 mg/m(2) on day 1, 5‐FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Lv5FU2-IRI (irinotecan 180 mg/m(2) on day 1, FA 200 mg/m(2), 5‐FU bolus 400 mg/m(2) and infused 5‐FU 600 mg/m(2) on day 1 and 2)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: FLIRI
Number of subjects: 567

Group type: COMPARATOR
Intervention: Lv5FU2-IRI
Number of subjects: 567
Study: 15180233

Group type: EXPERIMENTAL
Intervention: Early individualized postoperative occupational therapy (OT) program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 100
Study: 11281614

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2 x 500 mg tablets daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9885441

Group type: EXPERIMENTAL
Intervention: Response-oriented induction therapy consisting of doxorubicin, vincristine, cyclophosphamide, L-asparaginase, and prednisolone.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Response-oriented induction therapy with intrathecal chemotherapy on day 8.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Response-oriented induction therapy without intrathecal chemotherapy on day 8.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall survival and event-free survival (EFS) rates at 6 years.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Complete remission (CR) patients' survival rates.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Age and platelet count as prognostic factors.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Days to complete remission (CR) and age as favorable factors for DFS.
Number of subjects: 116
Study: 7994784

Group type: EXPERIMENTAL
Intervention: TUR + intravesical epirubicin (20 mg/40 ml, 30 times/2 years)
Number of subjects: 129

Group type: COMPARATOR
Intervention: TUR-alone group
Number of subjects: 129
Study: 2688083

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 31735542

Group type: EXPERIMENTAL
Intervention: Weight stigma news article (N=75)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Smoking stigma news article (N=97)
Number of subjects: 172
Study: 27604070

Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (no vitamin K supplementation)
Number of subjects: 401
Study: 25597266

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional restorative technique (CT)
Number of subjects: 99
Study: 23867958

Group type: EXPERIMENTAL
Intervention: Early surfactant use for respiratory distress syndrome, perinatal aspiration syndrome, and pneumonia/sepsis
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Early inhaled nitric oxide (iNO)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Oxygenation index (OI) <20 at enrollment
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Surfactant use before randomization
Number of subjects: 299
Study: 21224020

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 10mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 19241171

Group type: EXPERIMENTAL
Intervention: STI/HIV risk reduction group
Number of subjects: 522

Group type: COMPARATOR
Intervention: General health promotion group
Number of subjects: 522
Study: 16373993

Group type: COMPARATOR
Intervention: 0 g of alpha-cyclodextrin (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 g of alpha-cyclodextrin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 g of alpha-cyclodextrin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 g of alpha-cyclodextrin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: alpha-cyclodextrin (all doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher doses of alpha-cyclodextrin
Number of subjects: 10
Study: 15037882

Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with exercise level of 4186 kJ/week (1000 kcal/week)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with exercise level of 10465 kJ/week (2500 kcal/week)
Number of subjects: 202
Study: 10910003

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.04 IU/kg) for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9533345

Group type: EXPERIMENTAL
Intervention: 5% Amlexanox oral paste (Aphthasol)
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 1124

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1124
Study: 8276984

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.d. for 21 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.d. for 7 days (post-treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Control group Cl, n = 14)
Number of subjects: 21
Study: 2882767

Group type: EXPERIMENTAL
Intervention: i.v. temazepam (both injectable forms: 90% propylene glycol and 40% salicylic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: elixir preparation of temazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: capsule preparation of temazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. temazepam
Number of subjects: 0
Study: 28972803

Group type: EXPERIMENTAL
Intervention: Manual diameter measurements
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Semi-automatic volume measurements
Number of subjects: 93
Study: 26399958

Group type: EXPERIMENTAL
Intervention: Transcutaneous electroacupuncture (TEA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cold nutrient liquid
Number of subjects: 13
Study: 23929260

Group type: EXPERIMENTAL
Intervention: H-AGE meal (roasted)
Number of subjects: 19

Group type: COMPARATOR
Intervention: L-AGE meal (steamed)
Number of subjects: 19
Study: 22730632

Group type: EXPERIMENTAL
Intervention: Active distraction (EMLA plus videogame)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional care (EMLA only)
Number of subjects: 109
Study: 20483522

Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate at birth
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate during ventilation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate after compressions and ventilation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall heart rate assessments
Number of subjects: 61
Study: 18334867

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) in addition to mebeverine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mebeverine alone
Number of subjects: 0
Study: 15616772

Group type: EXPERIMENTAL
Intervention: BCG + FAM (immunochemotherapy)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: FAM (chemotherapy)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 156
Study: 11335732

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS solution
Number of subjects: 675
Study: 9267272

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia with a combination of lidocaine hydrochloride and bupivacaine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preemptive analgesia with saline solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 0
Study: 8387084

Group type: EXPERIMENTAL
Intervention: Clinic systolic blood pressure
Number of subjects: 97

Group type: COMPARATOR
Intervention: Daytime ambulatory blood pressure
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Sum of SV1 + RV5 (ECG voltages)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Residual ambulatory blood pressure levels
Number of subjects: 97
Study: 3554125

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium
Number of subjects: 133

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 133
Study: 30446405

Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN, Dentsply Sirona)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: One Shape (OS, Micro‐Mega)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: One G (OG) files (Micro‐Mega, Besançon, France)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: ProGlider (PG) files (Dentsply Sirona) with WaveOne Gold (WOG, Dentsply Sirona)
Number of subjects: 135

Group type: COMPARATOR
Intervention: K/OS and K/PTN
Number of subjects: 135

Group type: COMPARATOR
Intervention: K/PTN, K/OS, and OG/OS
Number of subjects: 135

Group type: COMPARATOR
Intervention: K/PTN and K/OS
Number of subjects: 135
Study: 29678195

Group type: EXPERIMENTAL
Intervention: Sensorimotor therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Attention‐matched motor therapy
Number of subjects: 60
Study: 27118620

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 364

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 364
Study: 24572702

Group type: EXPERIMENTAL
Intervention: Watermelon supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 13
Study: 22237688

Group type: EXPERIMENTAL
Intervention: Insulin glargine (G+MET)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NPH insulin (NPH+MET)
Number of subjects: 110
Study: 19417734

Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.10 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.075 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low-dose tirofiban
Number of subjects: 94
Study: 17448840

Group type: EXPERIMENTAL
Intervention: Postoperative Symptom Severity (PoSSe) scale
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Standardized surgical and analgesic protocols
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Clinical assessment of trismus and pain
Number of subjects: 255
Study: 15185887

Group type: COMPARATOR
Intervention: Stented xenografts (Group 1)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Stentless xenografts (Group 2)
Number of subjects: 668
Study: 11061578

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 mL double-strength three times a day for 3 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simvastatin 24 hours after grapefruit juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simvastatin 3 days after grapefruit juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simvastatin 7 days after grapefruit juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with simvastatin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simvastatin 3 or 7 days after grapefruit juice
Number of subjects: 10
Study: 9311179

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 microgram tablets)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel (1.5 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 110
Study: 8393389

Group type: EXPERIMENTAL
Intervention: Lisinopril therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lisinopril therapy in subjects with high norepinephrine levels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lisinopril therapy in subjects with low norepinephrine levels
Number of subjects: 14
Study: 2878272

Group type: EXPERIMENTAL
Intervention: Intrathecally administered natural human fibroblast interferon (IFN-B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 29346838

Group type: EXPERIMENTAL
Intervention: BMS-962212 (20 mg h-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28684128

Group type: EXPERIMENTAL
Intervention: Individual plus household MRSA decolonization
Number of subjects: 77

Group type: COMPARATOR
Intervention: Individual MRSA decolonization
Number of subjects: 77
Study: 25028958

Group type: EXPERIMENTAL
Intervention: High-protein low-fat (HPLF) diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-protein moderate-fat (MPMF) diet
Number of subjects: 13
Study: 23231446

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 21511818

Group type: EXPERIMENTAL
Intervention: HealthWise intervention
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 4040
Study: 18303467

Group type: EXPERIMENTAL
Intervention: Supervised Swiss ball exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise advice group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Supervised exercise and Exercise advice)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 60
Study: 17238380

Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System (CDSS)
Number of subjects: 90162

Group type: COMPARATOR
Intervention: No CDSS (Control)
Number of subjects: 90162
Study: 14996065

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment under occlusion for 48 h
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% ointment under occlusion for 48 h
Number of subjects: 28

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 28
Study: 10626714

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%/2 microg x ml(‐1) fentanyl
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bupivacaine 0.125%/2 microg x ml(‐1) fentanyl
Number of subjects: 32
Study: 9127122

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/day)
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Indobufen (200 mg/day)
Number of subjects: 1632
Study: 8233639

Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg q 12 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg q 12 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pefloxacin and Ofloxacin with Ketoprofen (100 mg daily)
Number of subjects: 10
Study: 31823745

Group type: EXPERIMENTAL
Intervention: Web-based sustainability intervention delivered to intervention clubs over three consecutive Australian winter sports seasons (April-September 2015-2017).
Number of subjects: 668

Group type: COMPARATOR
Intervention: Usual support from the national Good Sports Program (control group).
Number of subjects: 668
Study: 28947569

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 2
Study: 27044069

Group type: EXPERIMENTAL
Intervention: Participants who endorsed false beliefs about biological differences rated the black patient's pain as lower and made less accurate treatment recommendations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants who did not endorse false beliefs about biological differences rated the black patient's pain as higher.
Number of subjects: 0
Study: 25558905

Group type: EXPERIMENTAL
Intervention: Multi-vitamin-mineral preparation supplemented with 300 mg guarana (Ac)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Caffeine supplement (C)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo supplement (Pl)
Number of subjects: 56
Study: 22014645

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 76
Study: 19560638

Group type: EXPERIMENTAL
Intervention: BPTB autografts
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ST/G autografts
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 18575221

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Adapalene 0.1% gel for 6 weeks followed by tazarotene 0.1% cream for 6 weeks (switch therapy)
Number of subjects: 201
Study: 16009690

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12477620

Group type: EXPERIMENTAL
Intervention: ACE-I (5 mg of enalapril)
Number of subjects: 35

Group type: COMPARATOR
Intervention: MVI (multivitamin placebo)
Number of subjects: 35
Study: 10051800

Group type: EXPERIMENTAL
Intervention: Cochrane Reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochrane Handbook
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Software program for Cochrane Reviews
Number of subjects: 0
Study: 8963482

Group type: EXPERIMENTAL
Intervention: Convulsofin (test) tablets (2 tablets each containing 300 mg calcium valproate, 263.4 mg valproic acid)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Convulsofin (test) tablets
Number of subjects: 16

Group type: COMPARATOR
Intervention: ref.A (2 dragees each of 300 mg calcium valproate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: ref.B (600 mg sodium valproate in liquid form)
Number of subjects: 16
Study: 1785001

Group type: EXPERIMENTAL
Intervention: Intravesical chemo- and immunotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravesical cytostatics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guérin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adjuvant prophylactic treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment of T1G3 cancer
Number of subjects: 60
Study: 7023516

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study: 31362531

Group type: EXPERIMENTAL
Intervention: Short-duration HIIT (SDHIIT, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-duration HIIT (LDHIIT, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30
Study: 30830724

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 27783367

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intensive medical management (IMM)
Number of subjects: 71
Study: 26469986

Group type: EXPERIMENTAL
Intervention: Rapid combination antiretroviral therapy (ART) initiated by pregnant women
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ART or replacement feeding initiated by breastfeeding women
Number of subjects: 16
Study: 23379809

Group type: EXPERIMENTAL
Intervention: Knee-length shorts (SHORTS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Full-length pants (PANTS)
Number of subjects: 15
Study: 21864886

Group type: EXPERIMENTAL
Intervention: Combined modality integrative medicine (CM‐IM) including hypnosis, therapeutic massage, and healing touch with each cycle of chemotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined modality integrative medicine (CM‐IM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chemotherapy without CM‐IM
Number of subjects: 43
Study: 19645779

Group type: EXPERIMENTAL
Intervention: Fulvestrant (first line: 2%, second line: 40%, third line: 29%, fourth line: 22%, fifth line: 7%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fulvestrant (in patients with clinical benefit)
Number of subjects: 45
Study: 17915642

Group type: EXPERIMENTAL
Intervention: Test drug (loxoprofen 60 mg tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference drug (loxoprofen 60 mg tablets)
Number of subjects: 0
Study: 15548972

Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day) + Reduced-Dose Neoral (RDN)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Everolimus (3 mg/day) + Full-Dose Neoral (FDN)
Number of subjects: 111
Study: 11672943

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.16 mg (slow onset)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.8 mg (fast onset)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg (slow onset)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.25 mg (fast onset)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.4 mg (slow onset)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg (fast onset)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9141914

Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5 micrograms.kg‐1.min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dopexamine 1.0 micrograms.kg‐1.min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dopexamine 2.0 micrograms.kg‐1.min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dopexamine (all doses)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44